Jeffrey Hausdorff to Neoplasms
This is a "connection" page, showing publications Jeffrey Hausdorff has written about Neoplasms.
Connection Strength
0.064
-
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res. 2001 May; 7(5):1221-9.
Score: 0.039
-
Unmet analgesic needs in cancer patients. J Pain Symptom Manage. 1995 Feb; 10(2):113-9.
Score: 0.025